BACKGROUND: Surgery is critical in the management of gastro-oesophageal cancer, and the addition of neo-adjuvant chemotherapy has proved to be of benefit. The calpain system has been implicated in tumour progression and response to various anti-cancer therapies, and therefore expression of the system was determined in this tumour type. METHODS: Two cohorts of gastro-oesophageal adenocarcinomas were investigated for calpain-1, calpain-2, calpain-9 and calpastatin expression using conventional immunohistochemistry. 88 patients who received neo-adjuvant chemotherapy and 140 patients who received surgery alone were investigated using a tissue microarray approach. RESULTS: Calpain-1, calpain-2 and calpastatin expression was associated with adverse cancer-specific survival in the neo-adjuvant cohort (P = 0.004, P = 0.001 and P = 0.012 respectively); which remained significant in multivariate analysis (Hazard ratio (HR) = 0.337; 95% confidence interval (CI) = 0.140-0.81; P = 0.015, HR = 0.375; 95% CI = 0.165-0.858; P = 0.020 and HR = 0.481; 95% CI = 0.257-0.900; P = 0.022 respectively). Calpain-1 and calpastatin expression was also associated with adverse cancer specific survival in the primary surgery cohort (P = 0.001 and P = 0.013 respectively); which remained significant in multivariate analysis (HR = 0.309; 95% CI = 0.159-0.601; P = 0.001 and HR = 0.418; 95% CI = 0.205-0.850; P = 0.016 respectively). Calpain-9 expression was not associated with cancer-specific survival in the neo-adjuvant and primary surgery cohorts. CONCLUSION: Determining the expression levels of calpain-1, calpain-2 and calpastatin may provide clinically relevant prognostic information for gastro-oesophageal adenocarcinomas; these findings warrant further studies in larger cohorts of patients.
BACKGROUND: Surgery is critical in the management of gastro-oesophageal cancer, and the addition of neo-adjuvant chemotherapy has proved to be of benefit. The calpain system has been implicated in tumour progression and response to various anti-cancer therapies, and therefore expression of the system was determined in this tumour type. METHODS: Two cohorts of gastro-oesophageal adenocarcinomas were investigated for calpain-1, calpain-2, calpain-9 and calpastatin expression using conventional immunohistochemistry. 88 patients who received neo-adjuvant chemotherapy and 140 patients who received surgery alone were investigated using a tissue microarray approach. RESULTS:Calpain-1, calpain-2 and calpastatin expression was associated with adverse cancer-specific survival in the neo-adjuvant cohort (P = 0.004, P = 0.001 and P = 0.012 respectively); which remained significant in multivariate analysis (Hazard ratio (HR) = 0.337; 95% confidence interval (CI) = 0.140-0.81; P = 0.015, HR = 0.375; 95% CI = 0.165-0.858; P = 0.020 and HR = 0.481; 95% CI = 0.257-0.900; P = 0.022 respectively). Calpain-1 and calpastatin expression was also associated with adverse cancer specific survival in the primary surgery cohort (P = 0.001 and P = 0.013 respectively); which remained significant in multivariate analysis (HR = 0.309; 95% CI = 0.159-0.601; P = 0.001 and HR = 0.418; 95% CI = 0.205-0.850; P = 0.016 respectively). Calpain-9 expression was not associated with cancer-specific survival in the neo-adjuvant and primary surgery cohorts. CONCLUSION: Determining the expression levels of calpain-1, calpain-2 and calpastatin may provide clinically relevant prognostic information for gastro-oesophageal adenocarcinomas; these findings warrant further studies in larger cohorts of patients.
Authors: Sarah J Storr; Caroline M Woolston; Fabricio F T Barros; Andrew R Green; Mohamed Shehata; Stephen Y Chan; Ian O Ellis; Stewart G Martin Journal: Int J Cancer Date: 2011-03-08 Impact factor: 7.396
Authors: Sarah J Storr; Rabab A A Mohammed; Caroline M Woolston; Andrew R Green; Tim Parr; Inmaculada Spiteri; Carlos Caldas; Graham R Ball; Ian O Ellis; Stewart G Martin Journal: Breast Date: 2011-05-04 Impact factor: 4.380
Authors: David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman Journal: N Engl J Med Date: 2008-01-03 Impact factor: 91.245
Authors: Katarzyna Starska; Ewa Forma; Paweł Jóźwiak; Iwona Lewy-Trenda; Marian Danilewicz; Olga Stasikowska-Kanicka; Michał Skóra; Katarzyna Kolary; Jakub Miazga; Anna Krześlak; Magdalena Bryś Journal: Tumour Biol Date: 2016-07-25
Authors: Jillian Davis; Stewart G Martin; Poulam M Patel; Andrew R Green; Emad A Rakha; Ian O Ellis; Sarah J Storr Journal: BMC Cancer Date: 2014-12-23 Impact factor: 4.430
Authors: Caroline M Woolston; Srinivasan Madhusudan; Irshad N Soomro; Dileep N Lobo; Alexander M Reece-Smith; Simon L Parsons; Stewart G Martin Journal: Redox Biol Date: 2013-05-23 Impact factor: 11.799
Authors: Da Ma; Juan Fang; Ying Liu; Jing-Jing Song; Yan-Qiong Wang; Juan Xia; Bin Cheng; Zhi Wang Journal: Oncol Lett Date: 2017-04-03 Impact factor: 2.967
Authors: Xuan Pu; Sarah J Storr; Yimin Zhang; Emad A Rakha; Andrew R Green; Ian O Ellis; Stewart G Martin Journal: Apoptosis Date: 2017-03 Impact factor: 4.677
Authors: Sarah J Storr; Siwei Zhang; Tim Perren; Mark Lansdown; Hiba Fatayer; Nisha Sharma; Renu Gahlaut; Abeer Shaaban; Stewart G Martin Journal: Oncotarget Date: 2016-07-26